A Pilot, Randomized, Placebo-Controlled Trial of GC4419 (Avasopasem Manganese) in Patients With Critical Illness Due to SARS-CoV-2 Infection (COVID-19)

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 21 Mar 2022

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Avasopasem manganese (Primary)
Indications Adult respiratory distress syndrome; COVID 2019 infections; Hypoxic respiratory failure
Focus Therapeutic Use
Sponsors Galera Therapeutics

09 Jul 2021 Status changed from recruiting to discontinued.
10 Nov 2020 According to a Galera Therapeutics media release, data from this trial is expected in the first half of 2021.
18 Sep 2020 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com